IMVT
What one share of Immunovant holds
Biological Products, (No Diagnostic Substances)
Immunovant, Inc. (“Immunovant,” “we” or the “Company”) is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Our focus is on developing IMVT-1402 (imeroprubart), a potentially best-in-class inhibitor of the neonatal fragment crystallizable receptor (“FcRn”), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (“IgG”) antibodies.
Immunovant’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$2.82 |
|---|---|
| Cash and investments | $3.87 |
| Book value | $3.57 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1.29 | $0.00 | −$1.29 | — | $0.19 |
| 2020 | — | −$1.54 | $0.00 | −$1.24 | — | $1.72 |
| 2021 | — | −$1.22 | $0.00 | −$0.95 | — | $4.00 |
| 2022 | — | −$1.43 | $0.00 | −$0.97 | — | $4.03 |
| 2023 | — | −$1.71 | $0.00 | −$1.53 | — | $2.78 |
| 2024 | — | −$1.88 | $0.00 | −$1.55 | — | $4.24 |
| 2025 | — | −$2.73 | $0.01 | −$2.48 | — | $4.16 |
| 2026 | — | −$2.77 | $0.00 | −$2.23 | — | $4.18 |